## Yves D Pastore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10941903/publications.pdf

Version: 2024-02-01

19	656	933447	996975
papers	citations	h-index	g-index
19	19	19	740
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood, 2003, 101, 3294-3301.	1.4	140
2	Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood, 2003, 101, 1591-1595.	1.4	133
3	Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood, 2018, 131, 2183-2192.	1.4	121
4	The worldwide distribution of the VHL 598C>T mutation indicates a single founding event. Blood, 2004, 103, 1937-1940.	1.4	67
5	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica, 2019, 104, e51-e53.	3.5	46
6	Secondâ€line treatments in children with immune thrombocytopenia: Effect on platelet count and patientâ€centered outcomes. American Journal of Hematology, 2019, 94, 741-750.	4.1	37
7	Physician decision making in selection of secondâ€line treatments in immune thrombocytopenia in children. American Journal of Hematology, 2018, 93, 882-888.	4.1	30
8	Developing professional caregivers' empathy and emotional competencies through mindfulness-based stress reduction (MBSR): results of two proof-of-concept studies. BMJ Open, 2018, 8, e018421.	1.9	29
9	Fatigue in children and adolescents with immune thrombocytopenia. British Journal of Haematology, 2020, 191, 98-106.	2.5	18
10	Duration of neonatal oxygen supplementation, erythropoiesis and blood pressure in young adults born preterm. Thorax, 2020, 75, 494-502.	5.6	12
11	Characterization of the severe phenotype of pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, E281.	4.1	8
12	Clinical Characteristics and Quality of Life of Children with ITP Starting Second Line Treatments: Data from the ITP Consortium of North America ICON1 Study. Blood, 2016, 128, 249-249.	1.4	7
13	Quality of life is an important indication for secondâ€line treatment in children with immune thrombocytopenia. Pediatric Blood and Cancer, 2021, 68, e29023.	1.5	4
14	Changes in hair cortisol and self-reported stress measures following mindfulness-based stress reduction (MBSR): A proof-of-concept study in pediatric hematology-oncology professionals. Complementary Therapies in Clinical Practice, 2020, 41, 101249.	1.7	3
15	Iron Overload Is Highly Prevalent in All Disease Severity States in Pyruvate Kinase Deficiency (PKD). Blood, 2016, 128, 2430-2430.	1.4	1
16	A 15-year-old boy with sickle cell disease, chest pain and respiratory distress. Cmaj, 2017, 189, E1529-E1530.	2.0	0
17	Physician Factors Determining Treatment Decisions in Selecting Second Line Agents for Pediatric ITP. Blood, 2016, 128, 1008-1008.	1.4	0
18	Blood Group Genotyping to Prevent Alloimmunization in Children with Sickle Cell Disease. Blood, 2016, 128, 2486-2486.	1.4	O

#	Article	IF	CITATIONS
19	Comparison of Bleeding Tools in a Cohort of Pediatric Patients with ITP: Data from the Pediatric ITP Consortium of North America ICON1 Study. Blood, 2016, 128, 4752-4752.	1.4	O